Newcastle and Dublin Spinout Enoda Launches Patient Mobility Data Platform
Built on the €50m Mobilise-D research project, Enoda measures how patients move in everyday life to improve clinical trials.
- Enoda has spun out of University College Dublin and Newcastle University.
- Its technology was validated in a clinical study of 2,366 participants.
- Target conditions include Parkinson’s, multiple sclerosis and COPD.
Enoda, a healthtech spinout from University College Dublin and Newcastle University, has launched a platform that captures real-world patient mobility data for clinical trials.
Measuring movement outside the clinic
Mobility is often hard to measure accurately outside controlled clinical settings. Enoda’s platform gives pharmaceutical, medtech and clinical research organisations high-quality data on how treatments affect patients’ movement in daily life, for conditions such as Parkinson’s, multiple sclerosis and COPD.
Built on Mobilise-D
The company emerged from Mobilise-D, a five-year, €50m European research project on measuring mobility loss in people with chronic conditions. Its technology was validated in studies involving around 100 participants across six groups, and a clinical validation study of 2,366 participants across four disease groups.
Professor Lynn Rochester, professor of human movement science at Newcastle University, is a co-founder. The company is led by chief executive Michael McMahon and supported by NovaUCD, Newcastle Innovations and Enterprise Ireland.
